吉西他滨剂量对GP方案一线治疗晚期非小细胞肺癌的影响

目的总结高剂量与低剂量吉西他滨（GEM）联合顺铂（DDP）（GP方案）一线治疗晚期非小细胞肺癌（NSCLC）患者的近期疗效、毒性反应和总生存时间,评价GEM剂量在GP方案中的意义。方法回顾性分析我院收治的采用GP方案治疗的107例初治晚期NSCLC患者的临床资料。结果 GEM低剂量组患者近期有效率为30.9%,总的临床获益率为81.8%;高剂量组分别为28.8%和73.1%。患者平均随访3.33 a,低、高剂量组患者中位生存时间分别为652 d和331 d。高剂量组骨髓抑制较低剂量组严重。病理细胞学类型是影响GP方案晚期NSCLC患者生存的因素。结论 GP方案一线治疗晚期NSCLC安全、有效,是标准方案之一。

Influence of the dosage of gemcitabine on the gemcitabine combined with cisplatin in first-line treatment for advanced non-small cell lung cancer

Objective To observe the influence of the dosage of gemcitabine（GEM） on the GEM combined with cisplatin（DDP）（GP protocol） in first-line treatment for patients with advanced non-small cell lung cancer（NSCLC）.Methods Retrospectively review clinical data of 107 patients with advanced NSCLC treated with low or high dosage of GEM and DDP.Results The total clinical response rate of low dosage group was 30.9%,and clinical benefit rate was 81.8%;in high dosage group which were 28.8%,73.1% respectively.After median follow-up of 3.33 years,the median overall survival time in low and high dosage group was 652 days and 331 days respectively.Myelosuppression in high dosage group was more serious compared with low dosage group.During treatment of GP protocol for patients with advanced NSCLC,cytopathology type was the impact factor on survival.Conclusion GP protocol as first-line treatment for advanced NSCLC is effective and safe,which can be one of the standard chemotherapy protocols.